Corbus Pharmaceuticals to Release Phase 1a Results for CRB-913 on December 11, 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 10 2025
0mins
Source: Globenewswire
- Clinical Trial Progress: Corbus Pharmaceuticals plans to release the Phase 1a results for CRB-913 on December 11, 2025, prior to market open, marking a significant step in the company's ongoing research efforts in oncology and obesity.
- Webcast Arrangement: On the same day at 8:00 am ET, Corbus will host a conference call and live webcast to discuss the Phase 1 data, aiming to enhance investor transparency and confidence in the company's research advancements.
- Innovative Drug Mechanism: CRB-913 is an oral small molecule CB1 inverse agonist designed to have reduced brain penetration, which is expected to lower the risk of neuropsychiatric adverse events, thus providing a safer option for obesity treatment.
- Market Potential Outlook: CRB-913 has shown a significantly lower brain penetration rate in preclinical models compared to other experimental CB1 inverse agonists, potentially opening new growth opportunities for the company in the obesity treatment market.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like CRBP with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on CRBP
Wall Street analysts forecast CRBP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRBP is 46.71 USD with a low forecast of 38.00 USD and a high forecast of 53.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.700
Low
38.00
Averages
46.71
High
53.00
Current: 8.700
Low
38.00
Averages
46.71
High
53.00
About CRBP
Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company. The Company has a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The Company’s oncology pipeline comprises two experimental drugs targeting solid tumors: CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFB expressed on cancer cells. CRB-701 is a monoclonal antibody attached to a monomethyl auristatin E (MMAE) cytotoxic payload using a proprietary linker technology. The pipeline also includes CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. CB1 inverse agonism is a clinically validated mechanism to induce weight loss.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Corbus Pharmaceuticals: 46% Stake Held by Retail Investors Influencing Management
- Retail Influence: Corbus Pharmaceuticals has 46% of its shares held by retail investors, indicating significant influence over management and strategic decisions, which could drive the company towards more public-interest-aligned directions.
- Institutional Participation: Institutional investors own 23% of the company, which brings credibility from professional investors but also raises the risk of a 'crowded trade' in a company lacking a growth history.
- Hedge Fund Role: Hedge funds hold 24% of the shares and may attempt to influence management to create short-term value, particularly driven by major shareholders like Cormorant Asset Management and OrbiMed Advisors.
- Insider Ownership: Insiders own less than 1% of the company, which may challenge other shareholders in holding management accountable for decisions, especially given the market capitalization of only $156 million.
Continue Reading
Biotech Surge Post-Market: Inspira, MediciNova, and DiaMedica Therapeutics Among Top Performers
Biotech Stocks Performance: Several small-cap biotech and healthcare companies saw notable gains in after-hours trading, driven by recent corporate updates and clinical milestones.
Inspira Technologies Update: Inspira Technologies Oxy B.H.N. Ltd. rose 5.88% following a recent agreement for a registered direct offering and a Standby Equity Purchase Agreement, despite no new news on the day.
MediciNova's Clinical Trial Success: MediciNova, Inc. advanced 4.83% after successfully completing patient enrollment in its Phase 2 OXTOX study, which evaluates MN-166 for preventing chemotherapy-induced peripheral neuropathy.
DiaMedica's FDA Meeting: DiaMedica Therapeutics Inc. gained 2.89% after a productive pre-IND meeting with the FDA regarding its study of DM199 in preeclampsia, with an additional non-clinical study requested.
Continue Reading